Amgen Stock Sank 9.6% After Novartis’s Trial Failure and a Tavneos Suspension
Amgen Stock Sank 9.6% After Novartis’s Trial Failure and a Tavneos Suspension TIKR.com
Covered in this story
What has happened since
- Amgen is up 12.2% since this was published, 41 days ago.
- Novartis is up 13.3% since this was published, 41 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Amgen
- Cantor Fitzgerald: $432 → $440 by Oct 2027 · neutral via MarketBeat
- Wells Fargo: $432 → $430 by Oct 2027 · equal weight via MarketBeat
- Scotiabank: $432 → $500 by Oct 2027 · outperform via MarketBeat
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 49 stories mentioning Amgen, the earliest published 9 Oct 2026.
Summary aggregated from TIKR.com's public RSS feed. The full reporting belongs to TIKR.com — please read it on their site.